Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
IDELVION: A Comprehensive Review of Clinical Trial and Real-World Data.
Escobar M, Mancuso ME, Hermans C, Leissinger C, Seifert W, Li Y, McKeand W, Oldenburg J. Escobar M, et al. Among authors: seifert w. J Clin Med. 2022 Feb 18;11(4):1071. doi: 10.3390/jcm11041071. J Clin Med. 2022. PMID: 35207344 Free PMC article. Review.
Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Untreated Patients with Hemophilia B.
Lemons R, Wang M, Curtin J, Lepatan LM, Male C, Peyvandi F, von Depka Prondzinski M, Wang R, McKeand W, Seifert W, Oldenburg J. Lemons R, et al. Among authors: seifert w. TH Open. 2024 Mar 26;8(1):e155-e163. doi: 10.1055/s-0044-1781466. eCollection 2024 Jan. TH Open. 2024. PMID: 38532939 Free PMC article.
Long-Term Safety and Efficacy of Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Previously Treated Pediatric Patients with Hemophilia B: Results from a Phase 3b Extension Study.
Kenet G, Chambost H, Male C, Halimeh S, Lambert T, Li Y, Seifert W, Santagostino E. Kenet G, et al. Among authors: seifert w. Thromb Haemost. 2020 Apr;120(4):599-606. doi: 10.1055/s-0040-1705116. Epub 2020 Mar 17. Thromb Haemost. 2020. PMID: 32185782 Free article. Clinical Trial.
An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study).
Lissitchkov T, Klukowska A, Buevich E, Maltceva I, Auerswald G, Stasyshyn O, Seifert W, Rogosch T. Lissitchkov T, et al. Among authors: seifert w. J Blood Med. 2020 Oct 9;11:345-356. doi: 10.2147/JBM.S268907. eCollection 2020. J Blood Med. 2020. PMID: 33117020 Free PMC article.
Efficacy, Safety and Pharmacokinetic Results of a Phase III, Open-Label, Multicenter Study with a Plasma-Derived Von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Pediatric Patients <12 Years of Age with Hemophilia A (SWIFTLY-HA Study).
Djambas Khayat C, Iosava G, Romashevskaya I, Stasyshyn O, Lopez MJ, Pompa MT, Rogosch T, Seifert W. Djambas Khayat C, et al. Among authors: seifert w. J Blood Med. 2021 Jun 21;12:483-495. doi: 10.2147/JBM.S299130. eCollection 2021. J Blood Med. 2021. PMID: 34188580 Free PMC article.
209 results